STOK Stock Price, Stoke Therapeutics Inc Quote, Chart

Market Summary

USD12.20+0.65

Delayedas of 14 May 2024, 09:56 am

5.63%

STOK Alerts

2 major insider sales recently.

STOK Stock Price

View Fullscreen

STOK RSI Chart

STOK Valuation

Market Cap

602.0M

Price/Earnings (Trailing)

-5.55

Price/Sales (Trailing)

68.56

Price/Free Cashflow

-7.02

STOK Price/Sales (Trailing)

STOK Profitability

Return on Equity

-77.33%

Return on Assets

-52.89%

Free Cashflow Yield

-14.24%

STOK Fundamentals

STOK Revenue

Revenue (TTM)

8.8M

Rev. Growth (Yr)

-18.17%

Rev. Growth (Qtr)

50.46%

STOK Earnings

Earnings (TTM)

-108.5M

Earnings Growth (Yr)

-16.98%

Earnings Growth (Qtr)

2.17%

Breaking Down STOK Revenue

52 Week Range

12.55

(Low)(High)

Last 7 days

-2.9%

Last 30 days

-9.8%

Last 90 days

179.6%

Trailing 12 Months

0.7%

How does STOK drawdown profile look like?

STOK Financial Health

Current Ratio

5.43

STOK Investor Care

Shares Dilution (1Y)

17.95%

Diluted EPS (TTM)

-2.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	14.6M	12.6M	10.7M	8.8M
2022	0	0	0	12.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Stoke Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	ticho barry	acquired	6,000	0.6	10,000	chief medical officer
May 01, 2024	ticho barry	sold	-113,653	11.3653	-10,000	chief medical officer
Apr 17, 2024	skorpios trust	sold	-41,760,000	11.6	-3,600,000	-
Apr 01, 2024	ticho barry	sold	-124,684	13.2277	-9,426	chief medical officer
Apr 01, 2024	nash huw m.	sold	-811,212	13.2272	-61,329	coo & cbo
Apr 01, 2024	ticho barry	acquired	265	0.6	442	chief medical officer
Apr 01, 2024	nash huw m.	acquired	20,000	0.4	50,000	coo & cbo
Mar 28, 2024	allan jonathan	sold	-67,667	13.2009	-5,126	general counsel & corp sec
Mar 19, 2024	allan jonathan	sold	-14,325	6.0986	-2,349	general counsel & corp sec
Mar 19, 2024	tulipano stephen j	sold	-25,101	6.0986	-4,116	cfo

Which funds bought or sold STOK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	JPMORGAN CHASE & CO	reduced	-39.65	52,365	147,745	-%
May 10, 2024	PNC Financial Services Group, Inc.	unchanged	-	42.00	68.00	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	2.08	1,833,980	2,966,830	-%
May 10, 2024	OSAIC HOLDINGS, INC.	new	-	823	823	-%
May 10, 2024	BlackRock Inc.	added	87.28	41,252,400	52,089,300	-%
May 10, 2024	VANGUARD GROUP INC	added	4.07	14,488,900	23,160,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	15.91	88,292	133,002	-%
May 10, 2024	CITIGROUP INC	added	37.61	52,900	73,792	-%
May 09, 2024	Dorsey & Whitney Trust CO LLC	unchanged	-	89,115	146,002	0.01%
May 09, 2024	RHUMBLINE ADVISERS	added	2.19	349,743	565,239	-%

Are Funds Buying or Selling STOK?

Are funds buying STOK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STOK

No. of Funds

STOK Alerts

2 major insider sales recently.

Unveiling Stoke Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 18, 2024	skorpios trust	-	6,905,121	SC 13D/A
Feb 26, 2024	cowen financial products llc	5.77%	2,276,106	SC 13G
Feb 26, 2024	cowen financial products llc	8.3%	3,721,659	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	6.6%	2,956,918	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.3%	4,131,045	SC 13G/A
Feb 14, 2024	redmile group, llc	5.9%	2,625,506	SC 13G/A
Feb 09, 2024	morgan stanley	7.5%	3,358,375	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Nov 06, 2023	lynx1 capital management lp	6.0%	2,664,158	SC 13G
Feb 14, 2023	rtw investments, lp	9.8%	3,870,981	SC 13G/A

Recent SEC filings of Stoke Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 18, 2024	SC 13D/A	13D - Major Acquisition
Apr 18, 2024	4	Insider Trading

Peers (Alternatives to Stoke Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Stoke Therapeutics Inc News

Latest updates

Stoke Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	50.5%	4.00	3.00	3.00	4.00	5.00	3.00	3.00	3.00	3.00
Operating Expenses	0.6%	33.00	32.00	31.00	31.00	30.00	30.00	30.00	28.00	28.00
S&GA Expenses	-100.0%	-	11.00	10.00	10.00	10.00	9.00	10.00	10.00	9.00
R&D Expenses	2.7%	22.00	22.00	20.00	21.00	20.00	21.00	20.00	18.00	18.00
Net Income	2.2%	-26.37	-26.96	-24.54	-30.65	-22.54	-25.65	-26.11	-24.65	-24.65
Net Income Margin	-3.7%	-12.36*	-11.92*	-9.66*	-8.31*	-6.80*	-8.15*	-	-	-
Free Cashflow	-17.7%	-24.58	-20.88	-17.64	-22.64	-21.52	-22.78	-24.09	-20.61	32.00

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-10.1%	205	228	240	257	282	256	278	301	316	239	254	264	279	298	200	210	221	229	239	246	108
Current Assets	-10.2%	193	215	230	246	270	244	265	289	306	229	245	260	275	294	195	206	216	226	237	244	106
Cash Equivalents	-6.7%	179	191	190	192	190	114	113	68.00	84.00	145	149	169	268	287	191	202	211	222	233	243	105
Net PPE	-9.4%	5.00	6.00	6.00	6.00	7.00	7.00	7.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	1.00
Liabilities	-5.7%	65.00	69.00	67.00	67.00	68.00	71.00	73.00	77.00	76.00	21.00	16.00	9.00	6.00	12.00	7.00	7.00	6.00	4.00	5.00	5.00	2.00
Current Liabilities	15.5%	36.00	31.00	25.00	22.00	32.00	31.00	29.00	28.00	23.00	17.00	12.00	8.00	6.00	11.00	7.00	6.00	5.00	4.00	5.00	5.00	2.00
Shareholder's Equity	-12.0%	140	160	173	190	214	185	204	224	240	218	238	255	272	286	193	203	214	224	234	242	105
Retained Earnings	-6.6%	-428	-401	-374	-350	-319	-297	-271	-245	-220	-196	-171	-149	-127	-110	-95.72	-82.03	-69.07	-58.03	-47.87	-39.27	-25.71
Additional Paid-In Capital	1.3%	569	561	548	541	534	483	477	471	461	414	409	404	400	396	288	285	283	282	282	281	131
Shares Outstanding	1.3%	46.00	46.00	44.00	44.00	44.00	39.00	39.00	38.00	37.00	37.00	37.00	37.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	290	-	-	-	297	-	-	-	665	-	-	-	385	-	-	-	490	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-19.0%	-24,566	-20,649	-17,262	-21,800	-21,356	-22,373	-22,056	-19,928	32,491	-16,258	-14,682	-15,831	-20,136	-10,931	-10,873	-9,646	-10,771	-10,201	-8,048	-6,274	-6,532
Share Based Compensation	-10.7%	5,410	6,058	6,552	6,760	5,887	5,790	5,926	6,163	4,975	4,686	4,614	4,452	2,698	1,580	1,785	1,649	754	712	731	298	181
Cashflow From Investing	-32.4%	9,988	14,771	14,617	23,473	53,085	22,490	67,264	146	-135,782	11,797	-5,264	-82,755	-204	-90.00	-269	-81.00	-610	-569	-583	-392	-90.00
Cashflow From Financing	-76.6%	1,717	7,343	562	48.00	45,054	43.00	434	3,425	42,507	171	408	159	546	106,868	673	369	198	192	-1,000	150,638	-68.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

STOK Income Statement

2024-03-31

Consolidated statements of operations and comprehensive loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 4,216	$ 5,152
Operating expenses:
Research and development	22,368	19,631
General and administrative	10,220	10,211
Total operating expenses	32,588	29,842
Loss from operations	(28,372)	(24,690)
Other income (expense):
Interest income (expense), net	2,426	2,103
Other income (expense), net	(428)	42
Total other income (expense)	1,998	2,145
Net loss	$ (26,374)	$ (22,545)
Net loss per share, basic	$ (0.57)	$ (0.53)
Net loss per share, diluted	$ (0.57)	$ (0.53)
Weighted-average common shares outstanding, basic	46,246,889	42,536,474
Weighted-average common shares outstanding, diluted	46,246,889	42,536,474
Comprehensive loss:
Net Income (Loss)	$ (26,374)	$ (22,545)
Other comprehensive gain (loss):
Unrealized gain (loss) on marketable securities	24	577
Total other comprehensive gain	24	577
Comprehensive loss	$ (26,350)	$ (21,968)

STOK Balance Sheet

2024-03-31

Consolidated balance sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 178,581	$ 191,442
Marketable securities		9,952
Prepaid expenses	10,722	11,320
Other current assets	3,559	2,561
Deferred financing costs	402
Interest receivable	11	64
Total current assets	193,275	215,339
Restricted cash	569	569
Operating lease right-of-use assets	6,060	6,611
Property and equipment, net	5,278	5,823
Total Assets	205,182	228,342
Current liabilities:
Accounts payable	2,102	1,695
Accrued and other current liabilities	12,570	13,815
Deferred revenue - current portion	20,918	15,309
Total current liabilities	35,590	30,819
Deferred revenue - net of current portion	25,042	33,074
Other long term liabilities	4,208	4,884
Total long term liabilities	29,250	37,958
Total liabilities	64,840	68,777
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 46,498,077 and 45,918,233 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	568,560	561,433
Accumulated other comprehensive loss		(24)
Accumulated deficit	(428,223)	(401,849)
Total stockholders’ equity	140,342	159,565
Total liabilities and stockholders’ equity	$ 205,182	$ 228,342

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

CEO	Dr. Edward M. Kaye M.D., Ph.D.
WEBSITE	stoketherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	117

Stoke Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Stoke Therapeutics Inc? What does STOK stand for in stocks?

STOK is the stock ticker symbol of Stoke Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stoke Therapeutics Inc (STOK)?

As of Mon May 13 2024, market cap of Stoke Therapeutics Inc is 601.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers. The fair value of Stoke Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Stoke Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STOK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Stoke Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether STOK is over valued or under valued. Whether Stoke Therapeutics Inc is cheap or expensive depends on the assumptions which impact Stoke Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STOK.

What is Stoke Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, STOK's PE ratio (Price to Earnings) is -5.55 and Price to Sales (PS) ratio is 68.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STOK PE ratio will change depending on the future growth rate expectations of investors.